Drug Database
LA

lansoprazole + amoxicillin + clarithromycin (Lansap)

✓ Approved

Takeda · ATP4A · 小分子

什么是 lansoprazole + amoxicillin + clarithromycin?

lansoprazole + amoxicillin + clarithromycin 是一种小分子,由Takeda研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Lansap
公司Takeda
药物类别小分子
分子靶点ATP4A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

lansoprazole + amoxicillin + clarithromycin 作用于 1 个分子靶点:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lansoprazole + amoxicillin + clarithromycin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastric ulcer✓ Approved
Infections and infestationsHelicobacter infection✓ Approved

相关研究文献

PubMedJournal of clinical microbiology2026-07-27

Synonymous codon-optimized multiplex qPCR for simultaneous detection of Helicobacter pylori and precise drug resistance profiling in infected individuals.

Li Hui-Lan H-L, Fan Ya-Li Y-L, Zhong Tian T, Lin Bi-Yu B-Y et al.

Antibiotic-resistant Helicobacter pylori (H. pylori) represents a significant global challenge to the efficacy of eradication therapies, underscoring the urgent need for rapid and precise pretreatment resistance profiling. Traditional genotyping assays frequently neglect synonymous mutations, resulting in false-negative results and reduced diagnostic accuracy. In this study, we developed a single-tube, synonymous codon-optimized multiplex real-time PCR (qPCR) assay for the qualitative detection of H. pylori and the simultaneous identification of mutations associated with resistance to clarithromycin (23S rRNA gene) and levofloxacin (gyrA gene). The probe design was informed by clinical mutation data and synonymous codon usage patterns from 453 isolates, achieving over 98% coverage of naturally occurring variants. The assay exhibited high sensitivity (limit of detection: 2-20 copies/μL), excellent repeatability (coefficient of variation <5%), and robust specificity. Clinical validation using 316 gastric mucosal specimens demonstrated 97.47% concordance with a commercial infection detection kit and 100% and 98.08% agreement with Sanger sequencing for 23S rRNA and gyrA resistance genotyping, respectively. This assay effectively addresses the critical limitation posed by synonymous mutations, providing a rapid, reliable, and clinically accessible tool to guide personalized H. pylori eradication therapy and promote antimicrobial stewardship. Increasing antibiotic resistance in Helicobacter pylori has reduced the effectiveness of eradication therapy and highlights the need for accurate resistance profiling before treatment. However, current molecular assays may miss resistant strains because synonymous mutations in probe-binding regions may interfere with detection and produce false-negative results. In this study, we developed a single-tube multiplex real-time PCR assay that incorporates synonymous codon variation into probe design, enabling simultaneous detection of H. pylori infection and clarithromycin- and levofloxacin-resistance mutations. By using sequence data from 453 clinical isolates, this assay achieved broad coverage of naturally occurring variants and showed high analytical and clinical performance. This approach addresses an important diagnostic blind spot in H. pylori resistance detection and provides a practical tool for pretreatment resistance profiling, individualized therapy selection, and improved antimicrobial stewardship.

PMID 42505101
阅读全文 →
PubMedMicrobiology and immunology2026-07-27

Mycobacterium intracellulare M.i.198-A Promising Strain for Studying Pathogenesis of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD).

Tateishi Yoshitaka Y, Maekura Ryoji R, Nishiuchi Yukiko Y, Matsumoto Sohkichi S

In this review, we introduce a promising strain for studying pathogenesis of nontuberculous mycobacterial pulmonary disease (NTM-PD), Mycobacterium intracellulare M.i.198. M.i.198 was isolated from a patient with progressive Mycobacterium avium-intracellulare complex pulmonary disease (MAC-PD) in whom surgical operation was required to suppress disease progression. M.i.198 shows progressive illness in infected mice in terms of bacterial load, inflammation, and by high-dose inoculation, mortality as well. Although M.i.198 is resistant to clarithromycin, the pathogenicity of M.i.198 in mice indicates the high potency for use to evaluate drug efficacies in vivo. Furthermore, M.i.198 can be genetically manipulated, which is quite different from other MAC strains, especially those of M. avium subsp. hominissuis. We herein report the bacteriological findings, experimental virulence and functional genomic features of M.i.198 with a small review of MAC strains used for animal models of MAC-PD.

PMID 42504918
阅读全文 →
PubMedAntibiotics (Basel, Switzerland)2026-07-27

Evolution and Antimicrobial Resistance Profiles of Klebsiella spp. Infections in Companion Animals in the Iberian Peninsula.

Jiménez-Serrano María M, Vidal Anna A, Duran Inma I, Seminati Chiara C et al.

Antimicrobial resistance (AMR) in companion animals is an increasing concern within the One Health framework, particularly regarding opportunistic pathogens such as Klebsiella spp. This retrospective study evaluated the epidemiology, antimicrobial susceptibility profiles, and temporal resistance trends of Klebsiella spp. infections in dogs and cats across the Iberian Peninsula. A total of 809 clinical isolates collected between 2016 and 2024 and submitted to a private diagnostic laboratory in Barcelona were analysed. Klebsiella pneumoniae was the predominant species (70%), more frequently identified in cats (76%) than in dogs (68%). Dermatological and respiratory samples exhibited the highest prevalence of multidrug-resistant (MDR) isolates. Overall MDR prevalence was high, particularly in cats (51.1%; 95% CI 41.1-60.9%) compared with dogs (38.4%; 95% CI 34.1-42.8%) although it was not statistically significant. K. pneumoniae generally exhibited higher resistance rates than K. oxytoca, particularly to amoxicillin/clavulanic acid, first-/second-generation cephalosporins, third-/fourth-generation cephalosporins (3/4th GC), fluoroquinolones, and tetracyclines. In both bacterial species, resistance rates were consistently higher among feline isolates. In contrast, aminoglycosides and phenicols retained high activity against most isolates. Temporal analysis revealed a significant increasing resistance trend to amoxicillin/clavulanic acid, which is particularly concerning given the widespread use of this antimicrobial as a first-line treatment in small animal practice. However, resistance trend to aminoglycosides showed a significant decline. No significant temporal changes were detected for 3/4th GC and fluoroquinolones, suggesting the persistence of resistant populations within companion animals. Resistance to aminoglycosides and phenicols remained comparatively low in this study. Whereas critically important category B antimicrobials, such as 3/4th GC and fluoroquinolones, exhibited low to moderate effectiveness, raising concerns about their empirical use. These findings highlight the substantial AMR and MDR burden of K. pneumoniae in companion animals in the Iberian Peninsula and reinforce the need for prudent antimicrobial use, routine susceptibility testing, and integrated One Health surveillance strategies.

PMID 42505641
阅读全文 →
PubMedAntibiotics (Basel, Switzerland)2026-07-27

Association of Resistance-Associated 23S rRNA and gyrA Mutations with Antimicrobial Resistance and Eradication Outcomes in Helicobacter pylori.

Matei Sergiu Dorin SD, Ilias Tiberia T, Suciu Ramona Nicoleta RN, Suteu Corina C et al.

Background/Objectives: The increasing prevalence of antimicrobial resistance has become a major challenge in the management of Helicobacter pylori infection and is a leading cause of eradication failure. Resistance to clarithromycin and fluoroquinolones is primarily mediated by mutations in the 23S rRNA and gyrA genes, respectively. This study aimed to evaluate the prevalence of resistance-associated mutations in the 23S rRNA and gyrA genes, investigate their relationship with phenotypic antimicrobial resistance, assess their impact on eradication outcomes, and develop a prediction model for treatment failure. Methods: This retrospective real-world cohort study included 294 adult patients with confirmed H. pylori infection evaluated at the Oradea County Emergency Clinical Hospital, Romania, between November 2022 and November 2025. Clinical, endoscopic, histopathological, microbiological, molecular, and treatment outcome data were collected from medical records. Resistance-associated mutations in the 23S rRNA (A2143G, A2142G, and A2142C) and gyrA (N87K, D91G, and D91N) genes were analyzed and correlated with phenotypic antimicrobial resistance and eradication outcomes. Independent predictors of eradication failure were identified using multivariable logistic regression, and a prediction model was subsequently developed. Results: Overall, 101 patients (34.4%) harbored 23S rRNA mutations and 64 (21.8%) carried gyrA mutations, while 27 patients (9.2%) exhibited mutations in both genes. A2143G was the most frequent mutation (25.2%). Resistance-associated mutations showed strong concordance with phenotypic antimicrobial resistance. Patients with wild-type strains achieved eradication rates exceeding 90%, whereas significantly lower success rates were observed among patients carrying A2143G, A2142G, or gyrA mutations. Multivariable analysis identified previous eradication attempts (aOR 3.12, 95% CI 1.71-5.68), A2143G mutation (aOR 4.86, 95% CI 2.43-9.72), gyrA mutation (aOR 2.91, 95% CI 1.45-5.84), increasing age (aOR 1.03, 95% CI 1.01-1.05), and treatment with clarithromycin-based triple therapy (aOR 2.18, 95% CI 1.02-4.63) as independent predictors of eradication failure. The prediction model demonstrated excellent discriminatory performance (AUC 0.88, 95% CI 0.84-0.92), with a sensitivity of 82.5%, specificity of 80.1%, and satisfactory calibration (Hosmer-Lemeshow p = 0.68). Conclusions: Resistance-associated mutations in the 23S rRNA and gyrA genes are strongly associated with phenotypic antimicrobial resistance and reduced H. pylori eradication success. Molecular resistance testing may facilitate individualized treatment selection and improve clinical outcomes. The proposed prediction model, integrating clinical characteristics, treatment regimen, and molecular resistance markers, demonstrated excellent performance and may represent a useful tool for identifying patients at increased risk of eradication failure.

PMID 42505624
阅读全文 →
PubMedAntibiotics (Basel, Switzerland)2026-07-27

Antimicrobial Resistance Profiles of Bacterial Pathogens Associated with Acute Diarrheal Disease: A Three-Year Retrospective Study in a Romanian Tertiary-Care Hospital.

Borcan Alina Maria AM, Caravia Laura Georgiana LG, Secuiu Bianca B, Borcan Calin Andrei CA et al.

Despite its typically self-limiting course, acute diarrheal disease continues to be clinically relevant from an antimicrobial resistance surveillance perspective. In-depth analyses at a national level remain limited, with available Romanian studies from the last decade focusing on individual pathogens, often relying on a restricted isolate collection. In this context, we aimed to evaluate antimicrobial resistance profiles and distribution of Salmonella spp., Campylobacter spp., Escherichia coli, Yersinia spp. and Shigella spp. Data was obtained from records from the Microbiology Laboratory of a tertiary-care hospital serving the south region of Romania, over a 3-year period. Campylobacter spp. had high resistance rates to ciprofloxacin (81.65% for C. jejuni; 85.15% for C. coli) and tetracycline (44.65% for C. jejuni; 56.07% for C. coli). Erythromycin resistance remained low and stable over the study period, with no statistically significant temporal variation; however, C. coli isolates demonstrated significantly higher erythromycin (p = 0.001) and tetracycline (p = 0.008) resistance rates compared to C. jejuni. Overall Salmonella spp. resistance rate to ciprofloxacin was 46.00%, with higher resistance observed in serogroups C (63.64%) and D (52.53%) (p < 0.01). Ampicillin (AMP) resistance varied significantly across years and serogroups, with serogroup B consistently demonstrating higher resistance rates (40.48%) (p < 0.001). E. coli isolates reacting with pathotype-associated O antisera revealed high resistance levels to ampicillin (41.57%), amoxicillin-clavulanic acid (AMC) (38.73%) and sulfamethoxazole-trimethoprim (SXT) (19.25%), with low resistance levels to ciprofloxacin (9.04%) and ceftriaxone (CRO) (9.71%); no significant variation in resistance patterns was identified across years or serological pools, suggesting a relatively stable resistance profile over the study period. Yersinia spp. isolates showed no notable antimicrobial resistance levels. Shigella spp. isolates exhibited high resistance for ampicillin (78.57%), sulfamethoxazole-trimethoprim (68.75%), amoxicillin-clavulanic acid (50.00%) and ceftriaxone (35.41%). This study addressed a recognized gap in Romanian and Eastern European surveillance data and aims to contribute to a stronger evidence base for future epidemiological investigations and antimicrobial stewardship efforts. Resistance rates identified in our study may provide valuable information for comparison with data generated from veterinary, food and environmental surveillance programs, thereby supporting a more comprehensive understanding of antimicrobial resistance (AMR) epidemiology. These findings may additionally contribute to the development of coordinated strategies aimed at mitigating the emergence and spread of AMR.

PMID 42505595
阅读全文 →
PubMedAntibiotics (Basel, Switzerland)2026-07-27

Natural Deep Eutectic Solvent-Based Dispersive Liquid-Liquid Microextraction Coupled with UHPLC-MS/MS for the Determination of Antibiotic Residues in Food Products.

Mostafa Ahmed A, Shaaban Heba H, Alqarni Abdulmalik M AM, Alturki Mansour S MS et al.

The application of green analytical chemistry (GAC) principles is increasingly important in developing sustainable analytical practices for food safety monitoring. Natural deep eutectic solvents (NADESs) have emerged as green alternatives to conventional organic solvents. This study aimed to develop a sustainable analytical method for determining antibiotic residues in processed meat and frozen poultry products. A dispersive liquid-liquid microextraction (DLLME) procedure based on a NADES composed of anisaldehyde and decanoic acid (3:1, molar ratio) was coupled with UHPLC-MS/MS for the simultaneous determination of macrolides (clarithromycin, erythromycin), sulfonamides (sulfamethoxazole, sulfadimethoxine), and a fluoroquinolone (enrofloxacin) in food samples. Key extraction parameters, including NADES volume, vortex time, centrifugation time, sample amount, and pH, were optimized. The method was validated for linearity, accuracy, precision, and recovery and applied to real samples from the Saudi market. The method showed excellent analytical performance, with good linearity (R2 ≥ 0.9982), recoveries of 84.1-99.4%, and RSDs ≤ 5.75%. The target antibiotics were successfully quantified in processed meat and frozen poultry samples, confirming applicability. In addition, a comprehensive evaluation using eight assessment tools confirmed the method's environmental sustainability, practicality and innovation. The proposed NADES-based DLLME-UHPLC-MS/MS method is a rapid, sensitive, and eco-friendly alternative to conventional techniques for monitoring antibiotic residues in processed meat and poultry, supporting both food safety and GAC principles.

PMID 42505607
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lansoprazole + amoxicillin + clarithromycin